“If you don’t know where you are going, any road will get you there.” - Lewis Carroll

Strategic planning has been a necessary component in maintaining our focus on the UMDF Mission:

“To promote research and education for the diagnosis, treatment and cure of mitochondrial disorders and to provide support to affected individuals and families.”

Our strategic initiatives have resulted in the development of a UMDF Roadmap to treatments and cures. The roadmap will be presented visually at this year’s symposium depicting three main pillars:

- **Diagnosis**
  - Increase Awareness
  - Improving Diagnoses
  - Developing Tools to Measure Mitochondrial Health/Disease

- **Therapeutic Development**
  - Facilitating Drug Development
  - Identifying & Funding Gaps, from Basic Science to Clinical Trials

- **Patient Care**
  - Personalized Medicine
  - Patient/ Clinician Education
  - Developing Coordinated Care Models
  - Establishing Centers of Excellence

We will be identifying all the necessary building blocks in each of the three pillars identifying their current state; where are we today and what do we need to do to keep moving forward; and what assets do we currently have, what do we need, and what are the opportunities.

Due to the strong mission focus and tremendous efforts of so many dedicated Volunteers, Donors, Corporations and Foundations, the UMDF income from grants, donations, sponsorships, and fundraising events for 2014-15 was up nearly 9% from the previous year.

This increase enabled us to increase funding to our research program by 9.3%, or nearly $100k, including new research grants and the establishment of a UMDF Mitochondrial Disease Community Patient Registry (MDCR). We have also increased funding by 10%, or $130k, for important initiatives, including the quarterly Mitochondrial Congressional Caucuses in the nation’s capital, expansion of the Regional Symposia program for the education of families and clinicians, and the continuation of the Grand Rounds program.

Glancing back over the past 20 years, I want you to feel encouraged. At no time in the history of mitochondrial disease research has there been as much progress and interest in finding treatments. Pharmaceutical companies and academic research institutions are taking notice of the years of research supported by UMDF through your efforts resulting in four active clinical trials focused on treatments for mitochondrial disease. This unprecedented clinical trial activity demands support and increased
participation in our Patient Registry (MDCR). Pharmaceutical companies will only design trials if there are enough people to populate them.

With representation in every state and 152 countries, we will not rest on our successes but constantly strive to serve our members and supporters better every day. We continue to hone our messaging and focus to better meet mission success.

Our job is to move the science forward as quickly as possible, and the UMDF Roadmap will guide the way by Coordinating efforts, Communicating needs and Collaborating to ensure mission success.”

The French philosopher Auguste Comte had cures in mind when he said, “Every science consists in the coordination of facts; if the different observations were entirely isolated, there would be no science.”

Supporting and empowering you is our main focus as we continue to “coordinate” patients, physicians and researchers, allied health, pharmaceutical, diagnostic, and philanthropic communities, identifying and connecting needs with abilities and opportunities.

Mattie Stepanek who lost his battle with mitochondrial myopathy at the young age of thirteen said, “Unity is strength... when there is teamwork and collaboration, wonderful things can be achieved.” The result of coordination and communication is collaboration and Mattie was correct, “wonderful things can be achieved.” UMDF is collaborating with many entities to meet our mission:

Coordination, Communication and Collaboration, three C’s along the “Roadmap” that will help us achieve the fourth and most important C; CURE!

“Begin at the beginning,” the King said, very gravely, “and go on till you come to the end: then stop.”- Lewis Carroll

We firmly believe that with your continued help and support of the UMDF Mission, we will be successful in bringing beneficial results to the mitochondrial community as we build and follow the UMDF Roadmap toward treatments and cures. We are at the beginning, and we will not stop until we get to the end!

Sydney Harris said, “The two words ‘information’ and ‘communication’ are often used interchangeably, but they signify quite different things. Information is giving out; communication is getting through.” UMDF is committed to “getting through.” UMDF “communicates” its mission with the medical and pharmaceutical communities providing encouragement and resources addressing your needs.
More than 230 UMDF members and their families took part in the third “Day on the Hill” on June 18, 2015. UMDF Members were educated on the issues that are affecting the mitochondrial disease community and were instructed to provide three requests of their House Members and one for each U.S. Senator.

Among the “asks” for Congress was a request for each Member to join the Congressional Mitochondrial Disease Caucus. Currently, 20 members of Congress are active on the caucus. The goal for our “Day on the Hill” participants was to double the amount of Congressmen sitting on the caucus and participating in the numerous briefings held each year to educate elected officials about mitochondrial disease and its impact on individuals and families. UMDF members were also instructed to ask their Congressmen to sign onto a letter, written by Rep. Jim McGovern (D-MA-02) and Rep. Tim Murphy (R-PA-18) to the NIH Director Francis Collins, MD, PhD. The letter to Dr. Collins asked the NIH to ensure that each of the relevant NIH institutes issue mitochondrial specific Requests for Applications and Program Announcements in an effort to bolster inclusion of such research in their various research portfolios; utilize a portion of Common Fund resources to stimulate mitochondrial research; make the pre-clinical development of therapeutics for the treatment of mitochondrial diseases a focus area for the Therapeutics for Rare and Neglected Diseases (TRND) program within the National Center for Advancing Translational Sciences (NCATS); work to develop novel, safe and effective nutritional interventions for mitochondrial disease; and The Office of the Director should create a coordinator for mitochondrial research who is empowered to hold the various institutes accountable for their commitment and progress. Congress members were also asked to support the 21st Century Cures Act, which does several things to help with the clinical trial process and the review and approval of new drugs and biologicals.

For their meetings with U.S. Senators, UMDF members asked each to sign onto a similar letter to Dr. Collins. That letter was written and signed by Senator Barbara Boxer (above). Numerous Senators said they would review the letter and consider adding their name.
For some organizations, it takes years to have a disease or condition listed in what is known as the Congressionally Directed Medical Research Program (CDMRP). Beginning in 2008, the UMDF annually submitted information and language to key House and Senate members requesting that mitochondrial disease and dysfunction be added to the list of diseases that are eligible for research funding through the Department of Defense. With the help of Senators Richard Durbin (D-IL) and Lamar Alexander (R-TN), mitochondrial disease made the list for the first time in 2015. CDMRP was created by the Department of Defense in 1992. It was needed after a grassroots petition from the National Breast Cancer Coalition (NBCC). The petition secured more than 2.6 million signatures asking for more federal research dollars for breast cancer.

At the same time, two U.S. Senators, Tom Harkin (D-IA) and Alphonse D’Amato (R-NY), introduced legislation that was designed to repurpose military funds. They believed that since the Cold War was ending, those dollars could be put to better use. The legislation asked that the money be moved from the DoD to the National Institutes of Health (NIH) for breast cancer research. Both the petition and the legislation were not successful. Senators Harkin and D’Amato did not give up. They introduced an amendment to the DoD Appropriations Act to transfer $210 million within the DoD budget to a peer-reviewed cancer research program. The measure was overwhelmingly approved. Initially, the money would have gone to the NIH; but, when cancer researchers were asked how they would spend the money, they offered little change in research programming underway. Advocates decided they needed to go to the DoD when they said they would “fight hard to win the war on breast cancer.”

Over the years, the program at the DoD has grown from breast cancer to 41 different diseases that are eligible for $247.5 million dollars. Mitochondrial disease is now one of them, and the CDMRP is charged with managing the projects and the dollars. Since being listed and since it was through the effort of the UMDF, Defense Department officials reached out to us looking for help from the entire patient community. CDMRP looked for consumer reviewers for the research projects that are considered for this funding. They are also looking for scientific reviewers for potential research projects. UMDF assisted the DoD with that as well.

Path2Cures Roundtable

The United Mitochondrial Disease Foundation was one of several advocacy organizations invited by Rep. Tim Murphy (R-PA-18) to participate in a public round table discussion called #Path2Cures. The event, held in Pittsburgh on October 23, was organized by the Congressman to talk about ways to improve the discovery, development, and delivery of new medications and treatments.

The UMDF was represented at the roundtable discussion by UMDF CEO/Executive Director, Charles A. Mohan, Jr., Mohan was one of the leaders from 14 organizations chosen to participate. He urged representatives of the other organizations to become better advocates in order to move towards the advancement of treatment and cures.

“We’re not getting the funding or the attention we need, often because we’re immobilized or stuck in a wheelchair or a bed,” Mohan said. “Remember: the ark was built by amateurs; the Titanic was built by professionals.”

The #Path2Cures meeting was part of the Energy and Commerce Committee’s 21st Century Cures Initiative, which was started in early 2014 to identify and develop solutions to problems in current systems, find ways that Congress can foster medical innovation, and work towards the optimal balance between speed and safety in the drug and treatment approval process.
In FY 2014-2015, the UMDF provided support to our members in the following ways.

- We fielded close to 5,000 phone calls and emails, providing information and hope to patients, families, friends and caregivers.
- We mailed, at no charge, more than 20,000 important brochures, Initial Diagnosis packets, emergency room cards, books and pamphlets.
- We held more than 40 support group meetings across the country for patients and families, enabling close to 1,000 affected individuals
- We brought physicians to ten different cities through our Family Meetings, so almost 350 patients and families could have their important questions answered about their illness and treatment.
**Education & Support**

**Grand Rounds**
As part of the UMDF's Mission to provide education about mitochondrial disease, we conducted eight Grand Rounds events across the nation. Educating physicians and allied health personnel about mitochondrial disease is critical to expand faster diagnosis and treatment. The UMDF Grand Rounds, with generous support from various funders, enables us to introduce and/or broaden the knowledge base on mitochondrial diseases. Grand Rounds provides continuing education to health care providers on topics specific to mitochondrial disorders.

- **Milwaukee College of Wisconsin**
  - Milwaukee, WI
  - Dr. Marni Falk

- **Women and Children's Hospital of Buffalo**
  - Buffalo, NY
  - Dr. Bruce Cohen

- **Children's Hospital Colorado**
  - Aurora, CO.
  - Dr. Amy Goldstein

- **Molecular and Medical Genetics Grand Rounds**
  - Doernbecher Children's Hospital
  - Portland, OR
  - Dr. Bruce Cohen

- **Levine Children's Hospital**
  - Charlotte, NC
  - Dr. Bruce Cohen

- **Children's Hospital of Orange County**
  - Orange, CA
  - CHOC WEST
  - Dr. Bruce Cohen

- **University of Louisville**
  - School of Nursing
  - Louisville, KY
  - Dr. Bruce Cohen

- **University of Kansas Medical Center**
  - Kansas City, KS
  - Dr. Fran Kendall

**Family Meetings**
As part of the UMDF's Mission to provide education about mitochondrial disease, we conducted 10 Family Meetings around the country. The format for the family meeting is simple. We bring a mitochondrial medicine specialist to a city so that they can bring the latest information about mitochondrial disease directly to the patient community. Patients and families are able to have questions about their illness answered by the physician.

- **Memphis, TN**
  - Dr. Bruce Cohen

- **Milwaukee, WI**
  - Dr. Marni Falk

- **Buffalo, NY**
  - Dr. Bruce Cohen

- **Pittsburgh, PA**
  - Dr. Amy Goldstein

- **Aurora, CO.**
  - Dr. Amy Goldstein

- **Portland, OR**
  - Dr. Bruce Cohen

- **Charlotte, NC**
  - Dr. Bruce Cohen

- **Orange, CA**
  - Dr. Bruce Cohen

- **Louisville, KY**
  - Dr. Bruce Cohen

- **Kansas City, KS**
  - Dr. Fran Kendall
The arrival of over 500 researchers, clinicians and family members in June of 2015 at Mitochondrial Medicine 2015 in Herndon, VA, heralded the 17th annual symposium sponsored by UMDF. As usual, there were scientific and family oriented tracks and, as is customary for when the symposium is located nearby to Washington, DC, there was also a strong advocacy component via Day on the Hill, along with NIH-sponsored activities. The scientific registrants represented a truly international composition, with several participants traveling from as far away as Eastern and Southeast Asia. The scientific program was co-chaired by Drs. Marni Falk of the Children’s Hospital of Philadelphia and Danuta Krotoski of the National Institutes of Health. The first three days focused on the multitude of roles that mitochondria play within cells, while day four focused on the role of genetic counseling in mitochondrial disease and therapeutic development efforts. Close to 300 families participated in the family track. This track is not only an opportunity for families to network with each other, but to heard the latest information about the potential for therapies, treatments and potential cures.

What began as an idea in a strategic plan in 2012 materialized in the fiscal year 2014-15 with the creation of UMDF Regional Symposia. The first regional symposia, which featured a two day educational track for clinicians and physicians and a one day family education session, was held in in the Great Lakes Region. A second regional symposia was held in the Southeast Region in Atlanta. In some cases, patients and families who are dealing with mitochondrial disease are unable to travel to our annual meeting. Regional Symposia enables them to attend an educational session near their home. It also allows UMDF to educate more physicians and clinicians on a regional basis.
2015 Grant Award Winners

The United Mitochondrial Disease Foundation Research Grant program began in 1997 as a means to fund research toward diagnosis, treatments, and cures for mitochondrial disease. Since the program began, UMDF has funded more than $11 million in research projects. In FY2014-2015, the UMDF funded six research projects totaling $464,898. The projects were selected by the Grant Review Committee are:

John Christodoulou, Ph.D.
Children’s Hospital at Westmead
New South Wales, Australia
Chairman’s Award - $100,000

“All Utility of FGF21 and GDF15 as Diagnostic and Prognostic Biomarkers of Mitochondrial Respiratory Chain Disorders.”
Dr. Christodoulou will validate optimal methodology in a clinical diagnostic laboratory setting to determine the utility of measuring FGF-21 and GDF-15 as biomarkers of pediatric mitochondrial disease. This has become a major question in the field, as to how potentially useful in terms of sensitivity and specificity these biomarkers are for mitochondrial disease.

Daniel F. Bogenhagen, MD
Department of Pharmacological Sciences
Stony Brook University
$100,000

“Kinetics of Mitochondrial Complex Assembly.”
Dr. Bogenhagen is utilizing mass spectrometry techniques to study the assembly map of the mitoribosome as well as the mitochondrial respiratory complexes. The improved understanding of both of these mitochondrial construction projects will enhance the diagnosis and future therapy of mitochondrial disorders.

Peter W. Stacpoole, MD, Ph.D.
Department of Medicine
University of Florida
$24,898

“Validation of an Observer Reported Outcome (ObsRO) Measure of Home Functionality in Children with Pyruvate Dehydrogenase Complex Deficiency (PDCD).”
Dr. Stacpoole, in response to a specific request from the FDA for information from the patient or patient family to aid in regulatory decisions, has developed an innovative computer tool to track home functionality of pediatric PDCD patients. The pilot study in 10 PDCD families will test the feasibility of the survey instrument and refine it as needed for its eventual use in a planned Phase III trial of dichloroacetate (DCA). If the trial shows DCA is found safe and effective, it could lead to this drug being designated as the first FDA-approved therapy for PDCD.

Dr. Atif Towheed, Ph.D.
Department of Pathology and Laboratory Medicine
Children’s Hospital of Philadelphia
$70,000

“Allotopic RNA Rescue of LHON Mouse Model.”
The goal of Dr. Towheed’s work is to develop a novel gene therapy strategy for the treatment of Leber hereditary optic neuropathy (LHON) utilizing a mouse model developed in the labs of Dr. Douglas C. Wallace. If this therapeutic approach is successful it could inhibit the onset of the optic nerve pathology.

Sara M. Nowinski, Ph.D.
Department of Biochemistry
University of Utah
$70,000

“Characterizing the Function of the Atypical Mitochondrial Kinase ADCK3.”
The studies in Dr. Nowinski’s grant will improve the understanding of ADCK3 function in the synthesis of coenzyme Q and cerebellar ataxia. Additionally, better treatment strategies for mitochondrial disease could be developed in the future if new roles for ADCK3 are identified.

Anu Suomalainen Wartiovaara MD, Ph.D.
University of Helsinki, Finland.
$100,000

“Vitamins B as Therapy for Disorders with mtDNA Instability.”
Dr. Suomalainen Wartiovaara will utilize a mouse model to build upon preliminary results indicating that vitamins B, especially B3 (Niacin) play key metabolism regulatory roles in patients with mitochondrial myopathies. Pre-clinical data generated in mice will inform the creation of a follow-up human clinical trial on the impact of Niacin supplementation for the alleviation of symptoms due to mitochondrial disease.
The creation and launch of the Mitochondrial Disease Community Registry (MDCR) marks a significant milestone for those affected by mitochondrial disease.

For the first time in the brief known history of mitochondrial disease, our community is collecting and sharing data in a manner that will positively impact the development of treatments and cures. The registry is meant to be a community asset that all parties interested in improving the lives of patients affected by mitochondrial disease can rally around.

The UMDF is committed to long-term financial sponsorship, serving as the guardian of the data, and to overall coordination of the project. We selected the Genetic Alliance as a partner for this initiative because of their patient-focused philosophy. We share a vision with the Genetic Alliance that registry data belongs to no one other than the person who provided that data, and that a disease advocacy organization such as the UMDF is the ideal steward of such data. Whereas large academic, health and drug development organizations certainly possess at least partially altruistic motivations in addressing mitochondrial disease, a disease advocacy organization is singularly interested in facilitating the most rapid possible development of effective treatments and cures for those affected by mitochondrial disease.

So what is the MDCR, who should register and why is it important? The MDCR will collect patient-centric health data that will be utilized to develop treatments, identify new symptoms (leading to better diagnoses) and provide information to researchers that seek to study mitochondrial disease. The MDCR will also identify new patients in need of support from our community. Our goal is to identify and characterize every person affected by mitochondrial disease, no matter where they are located, living or deceased. Caregivers and family members of those affected, whether themselves affected or not, are also encouraged to register and contribute to the community. If we don’t share information, the chances of developing treatments and cures are greatly diminished.

The Mitochondrial Disease Community Registry: Our Disease. Your Information. Our Best Hope for Treatments and Cures!
Marriott Grant

The United Mitochondrial Disease Foundation is honored to report to our members that we have been awarded a nearly $1 million grant from the J. Willard and Alice S. Marriott Foundation. With the proceeds from the grant, the UMDF will be able to support our Patient-Populated Registry and Biobank Project and support the UMDF Mitochondrial Sequencing Data Resource Tool Project. These elements blend together to create a vision of the UMDF playing a critical central role in coordinating and facilitating the development of treatments and cures for the mitochondrial disease affected community. An equally important element in the overall therapeutic development strategy of the UMDF is the MSeqDR Project, which was initiated at the June 2012 Annual Meeting of the UMDF. This project, which engages and unites more than 100 international mitochondrial disease experts, creates an international genomic data resource for the mitochondrial disease community. It is the interplay of genomic and medical data (such as captured by NAMDC and the UMDF Patient-Populated Registry).

Treatments

Recently, the New York Times Magazine published an article entitled “The Brave New World of Three Parent I.V.F.” The article featured in vitro fertilization procedures where a woman’s eggs are extracted, and injected with her husband’s sperm and cytoplasm from another woman’s eggs with the result of a pregnancy following the implantation of the fertilized eggs. At the same time, the Food and Drug Administration is being asked to allow clinical trials for a new technique that replaces the mitochondria of a mother with the mitochondria of a donor. Researchers are hoping that this ‘mitochondrial replacement therapy’ (MRT) will prevent a variety of diseases caused by mutations in the mitochondrial DNA. Far from creating a “designer baby,” these are breakthroughs that can majorly and joyfully change the quality of life and longevity for a child or adult, much like stem cell and bone marrow transplants have done for those suffering with blood cancers. MRT technology will be beneficial to those who might carry disease, but even more exciting, understanding mitochondrial dysfunction and diseases has the potential to transform medicine and have a much broader impact on human health. The United Mitochondrial Disease Foundation (UMDF) maintains that every individual has the right to safe and effective health care as well as access to all current therapeutic innovations for the alleviation and prevention of mitochondrial diseases. We supported further scientific investigation of oocyte MRT as well as constructive debate towards the clinical approval of this therapy in women with mtDNA-related diseases. If demonstrated to be safe and efficacious, this technique should be made available as an option to families who carry mtDNA defects.
INDEPENDENT AUDITOR’S REPORT

To the Board of Trustees of the United Mitochondrial Disease Foundation, Inc.

We have audited the accompanying financial statements of the United Mitochondrial Disease Foundation, Inc. (the "Foundation") (a nonprofit organization), which comprise the statements of financial position as of June 30, 2015 and 2014, and the related statements of activities, functional expenses and cash flows for the years then ended, and the related notes to the financial statements.

Management’s Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditor’s Responsibility

Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity’s preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity’s internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the United Mitochondrial Disease Foundation, Inc. as of June 30, 2015 and 2014, and the changes in its net assets and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.
# Financials

## Statements of Financial Position

**June 30, 2015 and 2014**

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>$895,942</td>
<td>$819,414</td>
</tr>
<tr>
<td>Accounts receivable</td>
<td>43,295</td>
<td>12,020</td>
</tr>
<tr>
<td>Grants receivable (Note 3)</td>
<td>107,575</td>
<td>25,200</td>
</tr>
<tr>
<td>Pledges receivable (Note 4)</td>
<td>40,000</td>
<td>50,000</td>
</tr>
<tr>
<td>Inventories</td>
<td>38,690</td>
<td>41,779</td>
</tr>
<tr>
<td>Investments (Note 5)</td>
<td>1,867,114</td>
<td>1,820,018</td>
</tr>
<tr>
<td>Prepaid expenses</td>
<td>52,311</td>
<td>42,927</td>
</tr>
<tr>
<td>Fixed assets - net (Note 6)</td>
<td>85,948</td>
<td>140,487</td>
</tr>
<tr>
<td><strong>TOTAL ASSETS</strong></td>
<td>$3,130,875</td>
<td>$2,951,845</td>
</tr>
</tbody>
</table>

| **LIABILITIES AND NET ASSETS** |            |            |
| **LIABILITIES**             |            |            |
| Accounts payable            | $318,974   | $280,208   |
| Accrued liabilities         | 71,292     | 64,484     |
| Grants payable (Note 7)     | 1,185,577  | 1,169,880  |
| Deferred revenue            | 44,750     | 0          |
| **Total liabilities**       | 1,620,593  | 1,514,572  |

| **NET ASSETS**              | 998,874    | 1,088,250  |
| Temporarily restricted (Note 9) | 511,408    | 349,023    |
| **Total net assets**        | 1,510,282  | 1,437,273  |

| **TOTAL LIABILITIES AND NET ASSETS** | $3,130,875 | $2,951,845 |

See Independent Auditor's Report and Notes to the Financial Statements.
## Financials

### Part V: Statements Regarding Other IRS Filings and Tax Compliance

<table>
<thead>
<tr>
<th>Question</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>1a. Enter the number reported in Box 3 of Form 1096. Enter -0- if not applicable</td>
<td></td>
<td></td>
</tr>
<tr>
<td>b. Enter the number of Forms W-2G included in line 1a. Enter -0- if not applicable</td>
<td></td>
<td></td>
</tr>
<tr>
<td>c. Did the organization comply with backup withholding rules for reportable payments to vendors and reportable gaming (gambling) winnings to prize winners?</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>2a. Enter the number of employees reported on Form W-3, Transmittal of Wage and Tax Statements, filed for the calendar year ending with or within the year covered by this return</td>
<td></td>
<td></td>
</tr>
<tr>
<td>b. If at least one is reported on line 2a, did the organization file all required federal employment tax returns?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Note. If the sum of lines 1a and 2a is greater than 250, you may be required to e-file (see instructions)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3a. Did the organization have unrelated business gross income of $1,000 or more during the year?</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>b. If &quot;Yes,&quot; has it filed a Form 990-T for this year? If &quot;No,&quot; to line 3b, provide an explanation in Schedule O</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4a. At any time during the calendar year, did the organization have an interest in, or a signature or other authority over, a financial account in a foreign country (such as a bank account, securities account, or other financial account)?</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>b. If &quot;Yes,&quot; enter the name of the foreign country:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5a. Was the organization a party to a prohibited tax shelter transaction at any time during the tax year?</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>b. Did any taxable party notify the organization that it was or is a party to a prohibited tax shelter transaction?</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>c. If &quot;Yes,&quot; to line 5a or 5b, did the organization file Form 8886-T?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6a. Does the organization have annual gross receipts that are normally greater than $100,000, and did the organization solicit any contributions that were not tax deductible as charitable contributions?</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>b. If &quot;Yes,&quot; did the organization include with every solicitation an express statement that such contributions or gifts were not tax deductible?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7 Organizations that may receive deductible contributions under section 170(c).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>a. Did the organization receive a payment in excess of $75 made partly as a contribution and partly for goods and services provided to the payor?</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>b. If &quot;Yes,&quot; did the organization notify the donor of the value of the goods or services provided?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>c. Did the organization sell, exchange, or otherwise dispose of tangible personal property for which it was required to file Form 8282?</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>d. If &quot;Yes,&quot; indicate the number of Forms 8282 filed during the year</td>
<td></td>
<td></td>
</tr>
<tr>
<td>e. Did the organization receive any funds, directly or indirectly, to pay premiums on a personal benefit contract?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>f. Did the organization, during the year, pay premiums, directly or indirectly, on a personal benefit contract?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>g. If the organization received a contribution of qualified intellectual property, did the organization file Form 8899 as required?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>h. If the organization received a contribution of cars, boats, airplanes, or other vehicles, did the organization file a Form 1098-C?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8 Sponsoring organizations maintaining donor advised funds. Did a donor advised fund maintained by the sponsoring organization have excess business holdings at any time during the year?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9 Sponsoring organizations maintaining donor advised funds.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>a. Did the sponsoring organization make any taxable distributions under section 4966?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>b. Did the sponsoring organization make a distribution to a donor, donor advisor, or related person?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10 Section 501(c)(7) organizations. Enter:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>a. Initiation fees and capital contributions included on Part VIII, line 12</td>
<td></td>
<td></td>
</tr>
<tr>
<td>b. Gross receipts, included on Form 990, Part VIII, line 12, for public use of club facilities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11 Section 501(c)(12) organizations. Enter:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>a. Gross income from members or shareholders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>b. Gross income from other sources (Do not net amounts due or paid to other sources against amounts due or received from them)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12a. Section 4947(a)(1) non-exempt charitable trusts. Is the organization filing Form 990 in lieu of Form 1041?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>b. If &quot;Yes,&quot; enter the amount of tax-exempt interest received or accrued during the year</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13 Section 501(c)(29) qualified nonprofit health insurance issuers.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>a. Is the organization licensed to issue qualified health plans in more than one state?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14a. Did the organization receive any payments for indoor tanning services during the tax year?</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>b. If &quot;Yes,&quot; has it filed a Form 720 to report these payments? If &quot;No,&quot; provide an explanation in Schedule O</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

**United Mitochondrial Disease Foundation**

**Inc.**

**25-1767180**

**UMDF Annual Report 2014-2015**
## Financials

### Statements of Activities and Changes in Net Assets

#### For the Years Ended June 30, 2015 and 2014

<table>
<thead>
<tr>
<th></th>
<th>Temporary Restrictions</th>
<th>Temporarily Unrestricted</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Receivable</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Public Support and Revenue</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Support:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fundraising</td>
<td>$1,321,336</td>
<td>$221,561</td>
<td>$1,542,897</td>
</tr>
<tr>
<td>Contributions</td>
<td>$680,051</td>
<td>150</td>
<td>$680,201</td>
</tr>
<tr>
<td>In honor of</td>
<td>96,876</td>
<td>0</td>
<td>96,876</td>
</tr>
<tr>
<td>In memory of</td>
<td>102,195</td>
<td>0</td>
<td>102,195</td>
</tr>
<tr>
<td>In Kind</td>
<td>277,222</td>
<td>0</td>
<td>277,222</td>
</tr>
<tr>
<td>Grants</td>
<td>2,526,637</td>
<td>444,711</td>
<td>2,971,348</td>
</tr>
<tr>
<td>Cancellation of grants payable</td>
<td>223,222</td>
<td>223,222</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>$2,526,637</td>
<td>$444,711</td>
<td>$2,971,348</td>
</tr>
<tr>
<td><strong>Revenue</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Symposium and seminars</td>
<td>363,950</td>
<td>1,666</td>
<td>365,616</td>
</tr>
<tr>
<td>Sales</td>
<td>10,688</td>
<td>0</td>
<td>10,688</td>
</tr>
<tr>
<td>Total Revenue</td>
<td>$376,009</td>
<td>$1,666</td>
<td>$379,109</td>
</tr>
<tr>
<td><strong>Investment Income</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net unrealized gain (loss) on investments</td>
<td>(23,183)</td>
<td>0</td>
<td>(23,183)</td>
</tr>
<tr>
<td>Net realized gain (loss) on investments</td>
<td>(3,954)</td>
<td>0</td>
<td>(3,954)</td>
</tr>
<tr>
<td>Gain on disposal of fixed assets</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Net assets released from program restrictions</td>
<td>285,426</td>
<td>(285,426)</td>
<td>0</td>
</tr>
<tr>
<td>Total</td>
<td>$3,222,241</td>
<td>163,295</td>
<td>3,385,536</td>
</tr>
</tbody>
</table>

| **Total Support and Revenue** | $3,232,241             | 163,295                   | $3,395,536   |

| **Functional Expenses** |                          |                           |             |
| Research               | 1,014,232               | 0                         | 1,014,232   |
| Public Awareness       | 345,902                 | 0                         | 345,902     |
| Education/Member Support | 1,082,250             | 0                         | 1,082,250   |
| Total Supporting Services | 4,442,384             | 0                         | 4,442,384   |

| **Total Expenses** | $3,321,617             | 0                         | $3,321,617  |

| **Changes in Net Assets** |                          |                           |             |
| Total Revenue            | $3,385,536             | 0                         | $3,385,536  |
| Supporting services      | 2,442,384              | 0                         | 2,442,384   |
| Administrative and General | 376,420               | 0                         | 376,420     |
| Total                     | $3,222,241             | 0                         | $3,222,241  |

| **Net Assets** | $2,971,348             | 0                         | $2,971,348  |

Net assets released from program restrictions $285,426

See Independent Auditor's Report and Notes to the Financial Statements.
Donors

July 1, 2014 through June 30, 2015

Power Investors - $100,000 and above

The J. Willard & Alice S. Marriott Foundation

William Wright Family Foundation

Life Investors - $50,000 and $99,999

Edith L. Trees Charitable Trust

Reata Pharmaceuticals, Inc.

Energy Investors - $10,000 - $49,999

Astellas Pharma US

Mr. Peter Kelley

Robert J. Bauer Family Foundation

Mr. and Mrs. Gordon Kidd

Butterflies of Hope

Mr. Sebastiano Lopresti & Family

Charlotte Pipe & Foundry Company

Mrs. Molly Auth Manning

FedEx

Mr. and Mrs. Herbert Markley

Georgia Regents University

Josie Mazzo Children’s Charities

Grantham, Mayo, Van Otterloo

The Mix 101.9 - Chicago

Mr. and Ms. Thomas Hefferon

Sage Foundation

Mr. David Heikkinen and Dr. Ann Heikkinen

The Spartanburg County Foundation

Help Hailey Foundation

Tishcon Corp.

William S. Kallaos Family Foundation

Dr. and Mrs. L. Shaun Williams

Mr. Patrick Kelley

Hope Investors - $5,000 - $9,999

14 News - Evansville

Raptor Pharmaceuticals

Akron Children’s Hospital

Mr. and Mrs. Gene Schimpf

Aytu Bioscience

The Slow Bone

Baylor Miraca Genetics Laboratories

Mrs. Doris Snell

Mr. Arnold Brazell

Solace Nutrition

Mr. and Mrs. Steve Buenaga

Staples Oil Co

Canadian Pacific

Starfish Fund

Courtagen Life Sciences, Inc.

Sure Logistics, Llc

Emerson Process Management

Texas Chili Company

Extended Ag Services Inc.

Townsquare Media

First Tennessee Foundation

Universal Weather and Aviation Inc.

Mr. and Mrs. Peter Geisler

Unum-Charlotte

GeneDx

VOYA

Mr. and Mrs. Clayton Hardon

Mr. and Mrs. Austen Wright

Mr. and Mrs. Harry Weinrauch

Mrs. Margaret McMillan-Klagge

The Precision Divisions, Inc.

Mr. Laird Pendleton

Rachael’s Gift Inc.

Mrs. Molly Auth Manning

The Precision Divisions, Inc.
Donors

Friends - $1,000 - $4,999

A Tow Atlanta, Inc.
Abrahams, Kaslow & Cassman, LLP
Accurate Advertising
Mrs. Diane Aiello
Mr. and Mrs. Josh Albertson
Amazon Smile Foundation
American Endowment Foundation
American Water Charitable Foundation
Mr. and Mrs. Andy Anderson
AgriGold
Karol Augspurger
Austin Canvas & Awning
Automotive Rentals, Inc.
Mr. and Mrs. Tommy Baker
Ball Corporation
Bank of America
Ms. Paula Barnard
Barrett Johnston Martin & Garrison LLC
Rosemarie Bastone
The Baxter International Foundation
Baxter Pharmaceutical Solutions LLC
BAYADA Pediatrics
Mr. John Belk
Mr. and Mrs. Jeff Black
Mr. and Mrs. Brandt Blanken
Dr. and Mrs. James Bolton
Mr. Oscar Boultinghouse
Mrs. Debra Schindler-Boultinghouse
Bradley Arant Boult Cummings
Mr. and Mrs. Dan Braun
Ms. Annette Braverman
Mr. Mark Braverman
Mr. and Mrs. Alan Breslow
Mr. Robert Bromm
Mr. and Mrs. Rich Brotherton
Ms. Ann Bumstead
Burmans Community Pharmacy
Burns Family Charitable Foundation
The Michael J. and Vicki D. Burns Family Foundation
Mr. and Mrs. Kurt Byth
Capps Charitable Fund
Caring Hands Pediatric Day Health
Mr. Jeff Carter
Mr. and Mrs. R. Scott Cederburg
Center For Pediatric Therapy - Evansville
Ms. Marcy Chapman and Mr. Greg Ahrens
Mark A. Chapman Foundation
Dr. David Charney
Children of Light
Mr. and Mrs. Eric Chilton
Honey Chipman
Mr. and Mrs. Ronald Christenson
Cincinnati Children’s Hospital
Code and Coffee, LLC
Dr. and Mrs. Bruce Cohen MD
Mrs. Clarey Collins
Mr. James Collins
Ms. Kathryn Crawford
Crowe Horwath LLP
Dr. and Mrs. John Curran
Mr. Brian Dannemann
Deaconess Hospital Inc.
Delta Gamma Foundation
Mr. and Mrs. Ronald Deluca
Mr. Daniel C. Deufel
Mr. George Dennis
Deutsche Bank
Mr. and Mrs. John DiCecco
Admiral & Mrs. Dave Dobke
Dole Packaged Foods
Domtar Paper Company
Mr. Jim Dooley
Doral Corporation
Dorman High School
Mr. and Mrs. Christian Easton
Edison Pharmaceuticals Inc.
Ms. Kara Eichelkraut
Enterprise Holdings Foundation
Dr. Marni Falk and Mr. Scott Falk
Mr. Mike Felts
Fidelity Charitable Gift Fund
Mr. and Mrs. Brent Fields
Miss Tonya Flory
Mrs. Diane Fluty
Mr. and Mrs. Garret Flynt
Mr. and Mrs. Michael Foglia
Footprint Case Management
Mr. and Mrs. Milton Forman
Dr. and Mrs. Patrick Forrest
Four Seasons Wealth Management
Fraternal Order of Eagles
GE Foundation
Mr. Bob Garrett
Ms. Glenda Garrick
Mr. and Mrs. David Garrison
Donors

July 1, 2014 through June 30, 2015

Ms. Julie Gibbons
Mr. and Mrs. James Gibson
Mrs. Norma Gibson
Gillette Children’s Specialty Healthcare
Mr. Perry Glassgow
Mrs. Olga Goldberger
Carole Goldin
Goldman, Sachs & Co.
Mr. and Mrs. Sheldon Goldstein
Mr. and Mrs. David Gray
Mr. and Mrs. Michael Grealish
Green Oaks Hospital
Grinnell Mutual Reinsurance
Mrs. Tiffany Grove
Ms. Alice Hackett
Mr. Michael Hackett
Mrs. Anne Hall
Mr. and Mrs. Michael Hall
Mr. and Mrs. Edward Hardison
Mr. and Mrs. Hooper Hardison
Harvard Pilgrim Health Care Inc.
Joshua Helfrich Memorial and Scholarship Foundation
Hewlett-Packard Co. Foundation
Highland Pharmacy
Prof. W. Highsmith Jr.
Mr. and Mrs. Tom Hodge
Hoffman, Bricker & Adams, PC
The Hunt Michael Hollis Fund
Mr. and Mrs. Siegfried Hoppe
Horizon Pharma
Mr. and Mrs. Shawn Huddleston
Mr. and Dr. Khurram Hussain
IBM Corporation
Mrs. Marian Iak
Illinois Tool Works Foundation (ITW)
Mr. and Mrs. Jeff Irvin
James Street Tavern, Inc.
Mr. and Mrs. David Janes
Johnson & Johnson
Mr. T. David Johnson
K.P.B. Corporation
Mrs. Kathleen Kalinowski
Mr. and Mrs. William Kallaos Sr.
Mr. David Keane
Ms. Joanne Kelley
David & Paula Kirsch Family Fund
Kobelco Stewart Bolling, Inc.
Ms. Patricia Gordon and Mr. Alan Koreneff
Mr. and Mrs. Bob Kukla
Mr. and Mrs. Bob Ladd
Lalilab, Inc.
LAM Research Foundation
Latin Brothers Inc.
Dr. and Mrs. Troy Layton
Mr. and Mrs. Edgar Levy
Ms. Joanne Ligeros
The Lindsey Family
MFS Investment Management
Macy’s
Mrs. Jenny McCoy
Mr. Mikael McKendrick
Mr. and Mrs. Chris McKulka
Maddock Industries
Maloff Fine Jewelry
Marla Mann
Mr. and Mrs. Joe Marx
MassMutual
Mr. and Mrs. Martin Mathews
Medtronic
Mr. and Mrs. Jeff Mee
Mrs. Megan Meese
Meuse Family Foundation
MIAC Analytics
Ms. Kelley Michalski
Microsoft
Donald J. & Callista F. Milroy
Charitable Fund
Mitobridge
Mr. and Mrs. Charles A. Mohan Jr.
Mohan’s Restaurant
Mr. Robert Molinari
Mr. and Mrs. Michael Morell
Ms. Carla Mote
The Mouk Family
Mr. and Mrs. Brad Mountz
Mr. and Mrs. Jim Mowrer
Mr. and Mrs. Francis Mroz
Mr. Steve Mueller
The Mullin Family
Mr. Gene Myers
Mr. Wes Neighbors
Mr. David Neill
Neurology Wellness
New Albany Plain Local Schools
Mr. Don Newman
Next Yoga LLC
Nueces Valley Dental Assistant Association
OHL Foundation
Oak Island Presbyterian Church
Mr. and Mrs. Frank O’Connor
Oroboros Instruments
Mr. Joe Orr
Our Lady of the Lake Foundation
Mr. and Mrs. Dave Owen
Donors

July 1, 2014 through June 30, 2015

Mr. Martin Packouz
Palm Valley Lutheran Church
Edward C. Palmer Memorial Fund
Mr. and Mrs. Neal Palmer

Partnersfinancial Charitable Foundation
Mr. Mark Pawlowski
The Peachtree Club
Mr. Mike Petersen
Pi Foundation Inc

Gloria & Frank Pipp Family Foundation
Dr. Michelle Snyderman Platt
Mr. and Mrs. Bobbie Porter
Ms. Page Porter
Prem Corp
PriceWaterhouse Coopers
Ms. Jennifer Prince
Puget Sound Kidney Centers
Puryear Custom Pools
Mr. George Quinn
Drs. Lon and Rebecca Raby
Randolph School
Drs. Fred and JoAnn Reckling
Relaxed Atmosphere Memphis
Mr. and Mrs. Joseph Rice
Ms. Sheila Rinaberger
Ritterbush & Piotrowski, LLP
Roberts-Winegardner Funeral Home
Rodgers Builders, Inc.
Ms. Therese Roig
Mr. William Roney III
Roofing Consultants Ltd
Mr. and Mrs. Don Ryan
Rx-Benzer Care Pharmacy
S&T Bank Charitable Foundation
Saal Family Fund
Sabre Capital Corp
St. Bernadette Catholic School
St. Mary's Health System
St. Nicholas Philoptochos Society
Mr. William Sammons
Mr. and Mrs. Kelly Sanders
Mr. and Ms. Michael Sandman
Scharff Charitable Foundation
Mr. and Mrs. Richard Schemmel
Schuster Enterprises, Inc.
Mr. Lyle Schutte
Seattle Children’s Research Institute
Mr. and Ms. Pat Shelley
Ms. Cynthia Sickler
Ms. Catherine Sims
Mr. Robert Snell
Southern Ohio Bikers, Inc.
Ms. Bethany Stamper
Stanford University
Star Fuel Centers, Inc.
Mr. and Mrs. Peter Stathakis
Mr. Charles Steadman
Stealth BioTherapeutics
Mr. Timothy Steward
St. John’s Episcopal Church
Oklahoma City
Ms. Kara Strittmatter
Mr. Gregory Stromberg
Stromquist & Co. Inc.
Synovus
Mr. and Mrs. Andrew Theodore
Mr. and Mrs. Ken Tilford
Ms. Judy Toler
Mr. and Mrs. Charles Tompkins
Mr. Robert Tranbaugh
Transgenomic
Mr. Dan Trzeciak
Mr. and Ms. Robert Tuccillo
UAW Ford
UPMC
UnitedHealth Group
Usher Oil Company
Ms. Stephanie VanMeter
Mr. and Ms. Kent Varner
Veeva Systems
ViaGenetics
Mr. Ross Vitek
Mr. James Volker
Mr. and Mrs. Li Kan Wang
Wausau Financial Systems
Mr. Edward Weisiger
Mr. and Mrs. Shawn Welch
Wells Construction
Wells Family Fund
Mr. and Mrs. Phil Whatley
The Whitehouse Family
Mr. Donald Wilhelm
Ms. Rolanda Williams
Mr. and Mrs. Ronnie Wilson
The Wing Arts And Humanities Fund
Mr. and Mrs. Doug Woleben
Mr. and Mrs. W Dan Wright
Ms. Katherine Young
Mr. Earl Youmell
Mr. John Zetterower
Zippo Manufacturing Co.
Our Regional Coordinators and dedicated volunteer planning committees brought the Energy for Life Walkathon to 27 cities in 2014-2015! This year marked our fifth year of hosting Energy for Life Walkathons as a way to bring families and teams together to fundraise for the UMDF.

We had 581 teams walking with us to help raise over $1,152,036 and countless amounts of awareness through various means. Teams and individuals fundraised through a variety of ways, including social media, personal asks, letter and/or email campaigns or hosting wrap-around fundraising events. These wrap-around fundraising events included restaurant fundraising nights, yard/garage sales, percentage sales at local businesses, flamingo flocking and many more fun and unique events!

The following cities and regions were host to an Energy for Life Walkathon in 2014-2015:

- Akron
- Atlanta
- Birmingham
- Central Texas
- Charlotte
- Chicago
- Cincinnati
- Columbus, GA
- Dallas-Fort Worth
- Delaware Valley
- Detroit
- Evansville
- Houston
- Indianapolis
- Iowa
- Kansas City
- Milwaukee
- Minnesota
- Nashville
- New Orleans
- Omaha
- Pittsburgh
- San Francisco Bay Area
- Shreveport
- St. Louis
- Tampa Bay
- Western New York

To see a list of Energy for Life Walkathons in your area, visit www.energyforlifewalk.org
Third Party & Sanctioned Events

The UMDF utilizes third party and sanctioned events for areas without an Energy for Life Walkathon presence, families with Research Funds through the UMDF, as well as a plethora of other reasons. Over the past year the UMDF has had a variety of unique and interesting special event fundraisers all over the United States. These events have included, community walks, auctions, wine tastings, Golf events, races, UMDF’s Lightbulb and Coins for a Cure campaigns, and many others! The UMDF has been able to fundraise over $360,000 from third party events and over $140,000 from our sanctioned events!

What is the difference between a third party and sanctioned event? A third party event is completely organized and hosted by a group of volunteers. They communicate their date and location to the UMDF staff. The UMDF staff will then help them by putting their event on the official UMDF calendar and social media pages, as well as sending collateral if needed. A sanctioned event is a direct partnership between volunteers and UMDF staff, and the event is hosted in conjunction with the UMDF. The sanctioned event partners will work with the UMDF to create a budget, a website (if needed), as well as general planning, adding to the official UMDF calendar and social media, as well as having any official UMDF collateral sent.

The UMDF has had some amazing Special Event Partners! Do you have an idea for a special event? Contact Tara at TaraM@umdf.org to get started!

Activate Your Mitochondria

Since its creation in January of 2014 the UMDF’s Activate Your Mitochondria continues to grow. Activate Your Mitochondria is the perfect fundraising tool for active folks. Whether you are running marathons, biking, swimming, or hiking there are many ways to get involved! This year Activate Your Mitochondria has managed to raise over $65,000, and over $100,000 since it started a little over a year ago! Science has told us that exercising is the best way to keep your own mitochondria healthy!

If you would like to be active for those who cannot, please join us in Activating Your Mitochondria at www.umdf.org/activate.
Family Research Funds

UMDF Family Research Funds are established by families as a way to honor or memorialize a loved one affected by mitochondrial disease. Donations to one of the funds listed below ensures that the world’s top mitochondrial scientists are receiving the support they need to perform breakthrough research. Research Funds from July 1, 2014 to June 30, 2015:

The Alex Schumacher Research Fund
The Anthony Demarko Maccarelli Research Fund
The Ainsley Paige Higgins Research Fund
The Andrew Radney Research Fund
The Angelray Research Fund
The Ayden and Faith Hingsbergen Research Fund
The Bishop/Lauer Family Research Fund
The Brady Sterchi Family Research Fund
The Brandon David Harris Research Fund
The Brandon Heschel Leach Research Fund
The Breylon Senn Research Fund
The Brittany Wilkinson Research Fund
The Caleb Jacobs Research Fund
The Carter Buffum Research Fund
The Carter Lackey Research Fund
The Champions for Chad Research Fund
The Christopher Schindler Research Fund
The Cooper & Isla Watson Research Fund
The Corynna Strawser Research Fund
The Dawnta and Levi Kendall Family Research Fund
The Elena’s Hope Research Fund
The Elizabeth Piro Research Fund
The Emily Steadman Research Fund
The Emma Frances Dalton Research Fund
The Hunt Michael Hollis Research Fund
The Isabella Magee Research Fund
The Isabella Lin Ramirez Research Fund
The Isabelle Sherman Research Fund
The Jack Edwards Research Fund
The Jackson Rothschild Research Fund
The Jaethan Myers Research Fund
The Jaxon Sharma Research Fund
The John Geraci Research Fund
The Jonah Ritterbush Research Fund
The Jude Manley Research Fund
The Kaden Jarret Huddleston Fund
The Kaidon Andrew Stamper Fund
The Katherine Dickens Research Fund
The Kids Like Connor Research Fund
The Lauren Benney Research Fund
The Leslie Whitt-Williams Research Fund
The Lex Santo Research Fund
Lincoln’s Hope Research Fund
The Lindsey Norris Research Fund
The Logan Sloane Aronson Research Fund in Honor of Sydney Breslow
The Melissa Kieffer Research Fund
The Michael Angelo LoPresti Research Fund
The Nicholas James Torpey Research Fund
The Unstoppable Nina Hall Research Fund
The Oliver Scheier Research Fund
The Olivia Paige Goldberg Research Fund
The Rachael Albertson Research Fund
The Samuel Cutliff Research Fund
The Spry Research Fund
The T.J. Amber Research Fund
The Taryn Fogel Research Fund
The Will Martin Family Research Fund
The Will Woleben Family Research Fund
Administration

Scientific & Medical Advisory Board

Marni Falk, MD - Chair
The Children's Hospital of Philadelphia
Philadelphia, PA

Dwight Koerbel, MD, PhD
Duke University Medical Center
Durham, NC

Sumit Parikh, MD
Cleveland Clinic
Cleveland, OH

Andrea L. Gropman, MD, FAAP, FACMG
Children’s National Medical Center
Washington, D.C.

Mark Korson, MD
Genetic Metabolic Center for Education
Salem, MA

Russell P. Saneto, DO, PhD
Seattle Children’s Hospital
Seattle, WA

Richard H. Haas, MB, BChir
UCSD Medical Center
San Diego, CA

Giovanni Manfredi, MD, PhD
Weill Medical College of Cornell University
New York, NY

Fernando Scaglia, MD
Baylor College of Medicine
Houston, TX

Marcia Haigis, PhD
Harvard Medical School
Boston, MA

Robert McFarland, MA, MBBS, PhD, MRCP, MRCPCH
Wellcome Trust Centre for Mitochondrial Research
University of Newcastle upon Tyne
Newcastle upon Tyne, UK

Gerard Vockley, MD, PhD
University of Pittsburgh Medical Center
Pittsburgh, PA

Carla Koehler, PhD
University of California, Los Angeles
Los Angeles, CA

Edward E. McKee, PhD
Central Michigan University
Mt. Pleasant, MI

Richard J. Youle, PhD
NINDS - Porter Neuroscience Research Center
Bethesda, MD

Staff

- Charles A. Mohan Jr.
  CEO/Executive Director

- Mark Campbell
  Chief Financial Officer

- Philip Yeske, PhD
  Science and Alliance Officer

- Kara Strittmatter
  Meeting Event Director

- Clifford Gorski
  Director of Communications

- Tania Hanscom
  National Walk Manager

- Beth Whitehouse
  Director of Development

- Leslie Heilman, JD
  Associate Director of Development

- Donna Nameth
  Data Entry Manager

- Barbara Cullaj
  Administrative Assistant

- Janet Owens
  Executive Administrative Assistant

- Jeff Gamza
  Multimedia Coordinator

- Cassie Franklin
  Gift Officer

- Julie Hughes
  Development Associate

- Tara Maziarz
  Special Events Associate

- Anne Simonsen
  Regional Coordinator - Great Lakes

- Margaret Moore
  Regional Coordinator - Southeast

- Nicole McCaslin
  Regional Coordinator - Northeast